Show simple item record

dc.contributor.authorOlbjørn, Christine
dc.contributor.authorSmåstuen, Milada Cvancarova
dc.contributor.authorThiis-Evensen, Espen
dc.contributor.authorNakstad, Britt
dc.contributor.authorVatn, Morten H
dc.contributor.authorJahnsen, Jørgen
dc.contributor.authorRicanek, Petr
dc.contributor.authorVatn, Simen Svendsen
dc.contributor.authorMoen, Aina Elisabeth Fossum
dc.contributor.authorTannæs, Tone Møller
dc.contributor.authorLindstrøm, Jonas Christoffer
dc.contributor.authorSöderholm, Johan D.
dc.contributor.authorHalfvarson, Jonas
dc.contributor.authorGomollón, Fernando
dc.contributor.authorCasén, Christina
dc.contributor.authorKarlsson, Magdalena Kauczynska
dc.contributor.authorKalla, Rahul
dc.contributor.authorAdams, Alex T.
dc.contributor.authorSatsangi, Jack
dc.contributor.authorPerminow, Gøri Margrete
dc.date.accessioned2020-02-04T12:23:41Z
dc.date.accessioned2020-03-08T02:18:20Z
dc.date.available2020-02-04T12:23:41Z
dc.date.available2020-03-08T02:18:20Z
dc.date.issued2019-12-13
dc.identifier.citationOlbjørn C, Småstuen MC, Thiis-Evensen E, Nakstad B, Vatn MH, Jahnsen J, Ricanek P, Vatn S, Moen AEF, Tannæs T, Lindstrøm JC, Söderholm, Halfvarson J, Gomollón, Casén C, Karlsson MK, Kalla R, Adams, Satsangi J, Perminow GM. Fecal microbiota profiles in treatment-naive pediatric inflammatory bowel disease ? associations with disease phenotype, treatment, and outcome. Clinical and Experimental Gastroenterology. 2019;12:37-49en
dc.identifier.issn1178-7023
dc.identifier.issn1178-7023
dc.identifier.urihttps://hdl.handle.net/10642/8242
dc.description.abstractPurpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes. Patients and methods: Fecal samples were collected from 235 children below 18 years of age. Eighty children had Crohn’s disease (CD), 27 ulcerative colitis (UC), 3 IBD unclassified, 50 were non-IBD symptomatic patients, and 75 were healthy. The bacterial abundance of 54 predefined DNA markers was measured with a 16S rRNA DNA-based test using GA-Map™ technology at diagnosis and after therapy in IBD patients. Results: Bacterial abundance was similarly reduced in IBD and non-IBD patients in 51 of 54 markers compared to healthy patients (P<0.001). Only Prevotella was more abundant in patients (P<0.01). IBD patients with ileocolitis or total colitis had more Ruminococcus gnavus (P=0.02) than patients with colonic CD or left-sided UC. CD patients with upper gastrointestinal manifestations had higher Veillonella abundance (P<0.01). IBD patients (58%) who received biologic therapy had lower baseline Firmicutes and Mycoplasma hominis abundance (P<0.01) than conventionally treated. High Proteobacteria abundance was associated with stricturing/penetrating CD, surgery (P<0.01), and nonmucosal healing (P<0.03). Low Faecalibacterium prausnitzii abundance was associated with prior antibiotic therapy (P=0.001), surgery (P=0.02), and nonmucosal healing (P<0.03). After therapy, IBD patients had unchanged dysbiosis. Conclusion: Fecal microbiota profiles differentiated IBD and non-IBD symptomatic children from healthy children, but displayed similar dysbiosis in IBD and non-IBD symptomatic patients. Pretreatment fecal microbiota profiles may be of prognostic value and aid in treatment individualization in pediatric IBD as severe dysbiosis was associated with an extensive, complicated phenotype, biologic therapy, and nonmucosal healing. The dysbiosis persisted after therapy, regardless of treatments and mucosal healing.en
dc.description.sponsorshipThe study was partly funded by the EU FP7-Health-2012 project, IBD Character. Grant agreement no: 305676 (http://cordis.europa.eu/project/rcn/106191_en.html).en
dc.language.isoenen
dc.publisherDove Medical Pressen
dc.relation.ispartofseriesClinical and Experimental Gastroenterology;Volume 12
dc.rightsThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectDysbiosisen
dc.subjectCrohn’s diseaseen
dc.subjectUlcerative colitisen
dc.subjectProteobacteriaen
dc.subjectBiologic therapiesen
dc.subjectFaecalibacterium prausnitziien
dc.titleFecal microbiota profiles in treatment-naive pediatric inflammatory bowel disease ? associations with disease phenotype, treatment, and outcomeen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2020-02-04T12:23:41Z
dc.description.versionpublishedVersionen
dc.identifier.doihttps://dx.doi.org/10.2147/CEG.S186235
dc.identifier.cristin1708278
dc.source.journalClinical and Experimental Gastroenterology


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms.
Except where otherwise noted, this item's license is described as This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms.